# OnCo record nct05217446 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05217446/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05217446", "NCT05217446" ;
  schema:name "A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic"@en ;
  schema:alternateName "SEAMARK"@en ;
  schema:description "A phase 2 trial of Encorafenib, Cetuximab, Pembrolizumab in colorectal cancer, run by Pfizer, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05217446/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05217446> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2022-07-11" ;
  onco:cancers <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/braf-v600e-colorectal/>, <https://onco.cc/cancers/msi-high-colorectal/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:drugs <https://onco.cc/drugs/encorafenib/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/pfizer/> .